Health-related Quality of Life with Encorafenib plus Binimetinib for BRAFV600E Thyroid Cancer
Combination therapy of encorafenib plus binimetinib for unresectable BRAF V600-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.
Authors
- Iwao Sugitani (ORCID: https://orcid.org/0000-0001-5560-0706)
- Yasushi Shimizu (ORCID: https://orcid.org/0000-0003-2624-4305)
- Shigenori Kadowaki (ORCID: https://orcid.org/0000-0001-9923-5309)
- Hiroo Imai (ORCID: https://orcid.org/0000-0002-1319-724X)
- Shinji Ueno (ORCID: https://orcid.org/0009-0008-5343-2049)
- Shingo Tamura
- Naomi Kiyota
- Makoto Tahara
- Yoshinori Hirashima
- Akihiro Nishiyama
- Shunji Takahashi
- Ken-ichi Ito
Institutions
- Shinshu University (JP)
- National Kyushu Medical Center (JP)
- Kobe University Hospital (JP)
- Tohoku University Hospital (JP)
- Kanazawa University Hospital (JP)
- Ono Pharmaceutical (Japan) (JP)
- Kanazawa Medical University Hospital (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Tohoku Medical and Pharmaceutical University Hospital (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Nippon Medical School Hospital (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1530/etj-25-0273
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00